Monge MMI

Language: Spanish
References: 21
Page: 267-270
PDF size: 139.90 Kb.

ABSTRACT

The herpes zoster or shingles, is a reactivation of the varicella-zoster virus. It is estimated that more than 90% of the US population has serologic evidence of VZV infection and is consequently at risk for developing herpes zoster. Almost 50% of elderly patients with herpes zoster have complications and the severity also increase with aging. Acute neuritis and postherpetic neuralgia are the most weakening consequences of herpes zoster. The importance of complications and exacerbations of herpes zoster is the patientʼs disability for daily activities. The diseaseʼs poor evolution and the treatment limitations are very important for seeing herpes like a public health problem.

REFERENCES

1. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352:2266-2267

2. Arvin A. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361-381.

3. Donahue J, Choo P, Manson J, R Platt. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-1609.

4. Dworkin RH, Corbin AE, Young JP Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60:1274–1283.

5. Dworkin R, Portenoy R. Pain and its persistence in herpes zoster. Pain. 1996;67:241-251.

6. Fauci et Al. Harrison Principios de Medicina Interna. 14a. Edición McGraw-Hill Interamericana de España: Madrid, 1998.

7. Gallagher, R. Management of Neuropathic Pain: Translating Mechanistic Advances and Evidence-based Research into Clinical Practice. Clin J Pain 2006;22:S2–S8.

8. Gnann J, Whitley R. Herpes zoster. N Engl J Med. 2002;347:340-346.

9. Haanpää, M. et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998;51:1405-1411

10. Haanpää, M. et al. Motor involvement in acute herpes zoster. Muscle Nerve 1997;20:1433-1438.

11. Hardy I, Gershon A, Steinberg S, LaRussa P. The incidence of zoster after immunization with a live attenuated varicella vaccine: a study in children with leukemia. Varicella Vaccine Collaboration Study Group. N Engl J Med. 1991;325:1545-1550.

12. Jumaan A, Yu O, Jackson L, Bohlke K, Galil K, Seward J. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002-2007.

13. Jung B, Johnson R, Griffin D, Dworkin R. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62:1545-1551.

14. Kupila, L. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006;66:75-80.

15. Leinweber, B., Kerl, H., y Cerroni, L. Histopathologic Features of Cutaneous Herpes Virus Infections (Herpes Simplex, Herpes Varicella/Zoster) A Broad Spectrum of Presentations With Common Pseudolymphomatous Aspects. Am J Surg Pathol 2006;30:50–58.

16. Miller,A. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-587

17. Nahass, G. et al. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. JAMA. 1992;11:2541-2544.

18. Oxman, MN. et al. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. N Engl J Med 2005;352:2271-84.

19. Pickering LD, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:624-638.

20. Vasquez M, LaRussa P, Gershon A, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-855.

21. Yih W, Brooks D, Lett S, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68-76.